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Edited by Lukas HuberAbstract Although gemcitabine is a potent therapeutic agent in
the treatment of human non-small cell lung cancer (NSCLC),
resistance to gemcitabine is common. In this study, we investi-
gated the molecular mechanisms involved in acquired gemcita-
bine resistance against NSCLC cells. Gemcitabine-resistant
NSCLC H1299 cells (H1299/GR) were selected by long-term
exposure of parental H1299 cells to gemcitabine. The median
inhibitory concentrations of gemcitabine in H1299 and H1299/
GR cells were 19.4 and 233.1 nM, respectively. Gemcitabine in-
duced activation of c-Jun NH2-terminal kinase (JNK) in paren-
tal H1299 cells but not in H1299/GR cells after 48 h. Blocking
JNK activation by pretreatment with SP600125, a speciﬁc
JNK inhibitor, or by transfection with dominant-negative JNK
vectors abrogated gemcitabine-induced apoptosis in parental
H1299 cells as evidenced by interruption of caspase activation.
Transient transfection with a JNKK2–JNK1 plasmid expressing
constitutive JNK1 partially restored the eﬀect of gemcitabine in
H1299/GR cells. Our results indicate that gemcitabine-induced
apoptosis in human NSCLC H1299 cells requires activation of
the JNK signaling pathway. Attenuated JNK activation may
contribute to development of acquired gemcitabine resistance in
cancer cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Non-small cell lung cancer (NSCLC) is a major public
health problem and one of the leading causes of cancer
death worldwide [1]. Although various chemotherapeutic
agents and treatment regimens have improved outcomes
for patients with advanced NSCLC, the treatments ulti-
mately fail in most patients because of resistance or intoler-
able toxicity. Chemoresistance, whether inherent or acquired,Abbreviations: FACS, ﬂuorescence-activated cell sorting; IC50, 50%
inhibitory concentration; JNK, c-Jun NH2-terminal kinase; NSCLC,
non-small cell lung cancer; PI, propidium iodide; XTT, 2,3-bis[2-me-
thoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt
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doi:10.1016/j.febslet.2005.10.064is known to be a major reason for the failure of anticancer
therapies, and is due mainly to interruption of the apoptotic
signaling pathway [2].
Gemcitabine (2 0,2 0-diﬂuorodeoxycytidine) is a highly potent
anticancer agent that is used as a single agent or in combina-
tion with other chemotherapeutic agents, such as cisplatin
and docetaxel, against NSCLC [3–5]. The major eﬀect of gem-
citabine is arrest of DNA synthesis [6]. Gemcitabine also has
been reported to induce apoptosis in multiple myeloma cells
and pancreatic cancer cells through activation of caspase
[7,8]. The exact mechanisms by which NSCLC cells acquire
gemcitabine resistance are still unknown. Understanding this
molecular mechanism may lead to better therapeutic strategies
against NSCLC.
c-Jun NH2-terminal kinase (JNK), a subfamily of the mito-
gen-activated protein kinases (MAPKs), is an important medi-
ator of apoptotic signaling [9,10]. JNK has at least 10 isoforms
that are encoded by three genes, JNK1, JNK2, and JNK3 [11].
JNK1 and JNK2 are expressed in various tissues and play cru-
cial roles in many cellular events, including growth control,
development, and apoptosis [12]. Importantly, JNK activation
is required for induction of apoptosis by a number of stress
stimuli, such as ultraviolet radiation, growth factor with-
drawal, inﬂammatory cytokines, and chemotherapeutic agents
[11,13,14]. Recent reports have shown that attenuation of JNK
activation correlates with acquired resistance against several
chemotherapeutic agents, such as cisplatin and vinblastine
[15,16].
The purpose of our study was to characterize the mecha-
nisms involved in acquired resistance to gemcitabine in
NSCLC cell lines. We used gemcitabine-resistant lung cancer
cells generated by continuous exposure of gemcitabine-suscep-
tible H1299 cells to clinically relevant doses of gemcitabine.
We also compared expressions of various antiapoptotic and
proapoptotic molecules with JNK activation in parental
H1299 and gemcitabine-resistant H1299/GR cells. Our data
show that JNK activation is required for induction of apopto-
sis by gemcitabine in human lung cancer H1299 cells. In
gemcitabine-resistant H1299/GR cells, JNK activation by
gemcitabine treatment was markedly attenuated, which corre-
lated with decreased induction of apoptosis. Transient trans-
fection of a JNKK2–JNK1 plasmid expressing constitutive
JNK1 partially restored the eﬀect of gemcitabine in H1299/
GR cells. Thus, JNK activation may contribute to the acquisi-
tion of gemcitabine resistance in NSCLC cells.blished by Elsevier B.V. All rights reserved.
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2.1. Cells and culture conditions
Human NSCLC H1299 cells were routinely cultured in monolayers
in RPMI 1640 medium supplemented with 10% heat-inactivated fetal
calf serum (FCS), 25 mM HEPES, 100 units/ml of penicillin, and
100 mg/ml of streptomycin. Gemcitabine-resistant H1299 cells were
established from these cells by initially adding 1 nM gemcitabine to
the culture medium and thereafter escalating the dose to 100 nM. Cells
were maintained in the presence of 5% CO2 at 37 C.
2.2. Chemicals and antibodies
Gemcitabine was purchased from Eli Lilly (Indianapolis, IN), and
dissolved in phosphate-buﬀered saline solution (PBS) to a concentra-
tion of 10 mM. JNK-speciﬁc inhibitor SP600125 was purchased from
Calbiochem (La Jolla, CA), dissolved in dimethyl sulfoxide, stored
at 20 C, and protected from light. An equal volume of solvent
was used as a control. The following antibodies were used in western
blot analysis: anti-Bcl-2, Bcl-xL, Mcl-1, Bax, and caspase-3 (Santa
Cruz Biotechnology, Santa Cruz, CA); anti-XIAP (BD PharMingen,
San Diego, CA); anti-phospho-Akt, Akt, phospho-ERK, ERK, phos-
pho-JNK, JNK, phospho-p38, p38, phospho-c-Jun, phospho-ATF2,
and anti-caspase-9 (Cell Signaling Technology, Beverly, MA); anti-cas-
pase-8 (MBL International, Woburn, MA); and anti-b-actin and hem-
agglutinin (HA) (Sigma, St. Louis, MO).
2.3. Cell proliferation assay
The antiproliferative eﬀects of gemcitabine on NSCLC cell lines
were determined by the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-
tetrazolium-5-carboxanilide inner salt (XTT) assay. Cells (5 · 103)
were seeded in 100 ll of culture medium/well in 96-well ﬂat-bottomed
plates and treated the next day with the drugs at various concentra-
tions. After the indicated times, cells were washed once with PBS,
and cell viability was determined by colorimetric assay with the tetra-
zolium dye XTT using the Cell Proliferation Kit II (Roche Molecular
Biochemicals, Indianapolis, IN) according to the manufacturers pro-
tocol. The experiments were performed at least three times for each cell
line. Cell viability was calculated as 100 · Atreatment/Acontrol, where A is
the absorbance measured by using a microplate reader (Model MRX;
Dynatech Laboratories, Chantilly, VA) at 450 nm, with a reference
wavelength at 650 nm. The concentration of gemcitabine that inhibited
absorbance by 50% (IC50) was determined by using the CURVEEXPERT
Version 1.3 program.
2.4. Apoptosis assay
For detection of apoptosis, ﬁxed cells were resuspended in PBS con-
taining 10 lg/ml propidium iodide (PI) (Roche Diagnostics, Indianap-
olis, IN) and 10 lg/ml RNase A (Sigma–Aldrich) at 37 C for 30 min.
Cell-cycle analysis was performed by using an Epics Proﬁle II ﬂow
cytometer (Beckman Coulter, Fullerton, CA) with MULTICYCLE soft-
ware (Phoenix Flow Systems, San Diego, CA). Accumulation of sub-
G1 cells, a known indicator of DNA fragmentation and apoptosis,
was used to quantify apoptosis. All experiments were repeated at least
twice.
2.5. Plasmid transfection and adenovirus vector transduction
H1299 cells were transfected with a dominant-negative gene cloned as
either pLNCX-3X HA-p46JNK1a (dnJNK1, encoding an hemaggluti-
nin (HA)-tagged dominant-negative JNK1 mutant) or pLNCX-3X
HA-p54JNK2a (dnJNK2, encoding an HA-tagged dominant-negative
JNK2 mutant) [17] were kindly provided by Dr. L.E. Heasley (Univer-
sity of Colorado Health Sciences Center, Denver, CO). Stable transfec-
tants were selected for growth in the presence of 500 lg/ml G418. For
transient transfection, H1299/GR cells were transfected with pSRa3
HA–JNKK2–JNK1, which expresses JNKK2–JNK1 fusion protein
that has constitutive JNK1 activity [18]. Plasmid transfection was done
using FuGENE6 reagent (Roche Diagnostics).Fig. 1. Cytotoxicity of gemcitabine in H1299 and H1299/GR cells.
Cells were treated with various concentrations of gemcitabine for 72 h
and cell viability was determined by XTT assay. Cells treated with PBS
were used as a control, with viability set at 100%. Each data point
represents the means ± S.D. of three independent experiments.2.6. Western blot analysis
For preparation of whole-cell extracts, cells were washed twice in
cold PBS, collected, and subjected to lysis in lysis buﬀer (62.5-mM Tris
[pH 6.8], 2% sodium dodecyl sulfate, and 10% glycerol) containing1 · proteinase-inhibitor cocktail (Roche). The lysates were spun at
14000 · g in a microcentrifuge at 4 C for 10 min, and the supernatants
were used as whole-cell extracts. Protein concentrations were deter-
mined by using the BCA Protein Assay Kit (Pierce, Rockford, IL).
Equal amounts (50 lg) of proteins were used for immunoblotting, as
described previously [19].3. Results
3.1. Eﬀect of gemcitabine on cell proliferation in H1299 and
H1299/GR cells
To investigate the mechanisms of acquired resistance to
gemcitabine in cancer cells, we generated a tissue culture model
(H1299/GR cells) by repeated treatment of H1299 cells with
gemcitabine. The cells were initially treated with 1 nM gemcit-
abine, and then surviving cells were treated with escalating
doses of gemcitabine, up to 100 nM. We ﬁrst checked the cyto-
toxic eﬀect of gemcitabine in H1299 and H1299/GR cells. Cells
were treated with various doses of gemcitabine for 72 h, and
then cells viability was determined by XTT assay. As shown
in Fig. 1, 100 nM gemcitabine inhibited the growth of H1299
cells after 72 h. In contrast, H1299/GR cells, which were se-
lected in a ﬁnal gemcitabine concentration of 100 nM, were
markedly resistant to 100 nM gemcitabine compared with
parental H1299 cells. The IC50 value of gemcitabine in
H1299/GR cells was consistently more than 10 times higher
than that in H1299 parental cells. The IC50 values of H1299
and H1299/GR cells were 19.4 and 233.1 nM, respectively.
3.2. Gemcitabine-induced apoptosis via activation of caspases in
H1299 cells
To elucidate the contribution of apoptosis induction to gem-
citabine-mediated cell death, we determined the proportions of
the sub-G1 populations in H1299 and H1299/GR cells treated
with gemcitabine by ﬂow cytometry assay or western blot anal-
ysis. Cells were treated with 100 nM gemcitabine for 24, 48, or
72 h. Cells were then harvested for quantitation of apoptotic
cells by ﬂow cytometry. In H1299 cells treated for 48 and
72 h, the portions of sub-G1 cells were 27.1% and 49.9%,
respectively; however, no sub-G1 cells were observed in gemcit-
abine-treated H1299/GR cells (Fig. 2A). To further examine
the ability of gemcitabine to induce apoptosis, we treated
Fig. 3. Expression of antiapoptotic and proapoptotic proteins in
H1299 and H1299/GR cells. Whole-cell lysates were analyzed by
immunoblotting with anti-Bcl-2, Bcl-xL, Mcl-1, Bax, and XIAP
antibodies. b-Actin was used as the loading control.
Fig. 2. Gemcitabine-induced apoptosis via caspase activation in H1299 cells. (A) Flow cytometry analysis of H1299 and H1299/GR cells treated with
100 nM gemcitabine for the indicated time periods. Cells were harvested, ﬁxed, and stained with PI. Histograms represent DNA contents. The
numbers represent the percentages of sub-G1 cells. (B) H1299 and H1299/GR cells were treated with 100 nM gemcitabine for the indicated time
periods, and proteins in whole-cell lysates were analyzed by immunoblotting with anti-caspase-3, caspase-8, and caspase-9 antibodies. The
arrowheads represent cleavage proteins. b-Actin was used as a loading control.
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48 h and evaluated cleavage of caspase by Western blotting.
Cleavage of caspase-3, caspase-8, and caspase-9 was clearly
detectable in H1299 cells after 48 h of treatment, but not in
H1299/GR cells (Fig. 2B). These results suggest that gemcita-
bine-induced apoptosis through caspase activation in H1299
cells.
3.3. Expression of antiapoptotic proteins in H1299 and
H1299/GR cells
To examine the correlation between gemcitabine resistance
and the levels of some antiapoptotic and proapoptoric pro-
teins, we compared the expression levels of Bcl-2, Bcl-xL,
Mcl-1, Bax, and XIAP in H1299 cells with those in H1299/
GR cells by Western blot analysis. As shown in Fig. 3, no dif-
ferences were seen between parental H1299 cells and gemcita-
bine-resistant H1299/GR cells.
3.4. Activation of JNK signaling pathway by gemcitabine
treatment in H1299 cells, but not in H1299/GR cells
To clarify the potential involvement of various protein ki-
nase signaling pathways in gemcitabine-resistant cells, we next
examined the eﬀect of gemcitabine on MAPK and Akt activa-
tion in H1299 and H1299/GR cells. The cells were treated with
100 nM gemcitabine for 48 h, and then cell lysates were sub-
jected to determination of phosphorylation status of JNK,
ERK, p38, and Akt by Western blotting (Fig. 4A). The basal
level of phosphorylated ERK expression in H1299 cells was
markedly higher than that in H1299/GR cells. Gemcitabinehad little eﬀect on phosphorylated Akt, but markedly in-
creased the level of phosphorylated JNK or p38 in H1299 cells
compared with those treated with solvent alone. Phosphory-
lation of p38 was also observed in H1299/GR cells after
gemcitabine treatment. However, gemcitabine-induced JNK
Fig. 4. Gemcitabine treatment activated the JNK signaling pathway. (A) Eﬀects of gemcitabine onMAPK and Akt activity in H1299 and H1299/GR
cells. Cells were treated with 100 nM gemcitabine (Gem) for 48 h, and then whole-cell lysates were subjected to western blotting using phospho-
speciﬁc and total protein antibodies to JNK, ERK, p38, and Akt. (B) Time-dependent activation of the JNK signaling pathway by gemcitabine
treatment. H1299 and H1299/GR cells were treated with 100 nM gemcitabine for the indicated time periods. Cell lysates were then subjected to
western blotting using total JNK and phospho-speciﬁc antibodies to JNK, c-Jun, and ATF2. Maximal phosphorylation of those molecules is
observed in H1299 cells treated with gemcitabine for 48 h.
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H1299/GR cells. We further examined time-dependent changes
in the molecules in JNK signaling pathway, including phos-
phorylated JNK, c-Jun, and ATF2 in gemcitabine-treated
H1299 or H1299/GR cells (Fig. 4B). Although JNK was
clearly detectable in both H1299 and H1299/GR cells, phos-
phorylated JNK was increased only in H1299 cells after 24
or 48 h of treatment. Moreover, phosphorylated c-Jun and
ATF2, which are downstream targets of the JNK signaling
pathway, were also observed in H1299 cells after 24 and 48 h
of treatment, but not in H1299/GR cells. These results indicate
that gemcitabine activates JNK and p38 signaling pathways,
and that lack of JNK activation is likely to correlate with gem-
citabine resistance in this cell system.
3.5. Inhibition of JNK activation blocks gemcitabine-induced
apoptosis with inhibiting caspase activation
To clarify the role of JNK activation in gemcitabine resis-
tance, we tested the eﬀect of SP600125, a novel speciﬁc
inhibitor of JNK, on JNK activation and apoptosis induction
by gemcitabine treatment. Pretreatment with 20 lM of
SP600125 markedly blocked phosphorylation of JNK, c-Jun,
and ATF2 after 48 h, but not total JNK protein (Fig. 5A), sug-
gesting that 20 lM of SP600125 was suﬃcient to block activa-
tion of JNK by gemcitabine. We then examined the eﬀect of
SP600125 on gemcitabine-induced apoptosis. H1299 cells were
exposed to gemcitabine for 48 h in the presence or absence of
20 lM SP600125, and were quantiﬁed by ﬂuorescence-acti-
vated cell sorting (FACS) analysis. SP600125 alone had little
eﬀect on H1299 cells. Pretreatment of H1299 cells with20 lM SP600125 markedly diminished gemcitabine-induced
apoptosis after 48 h (Fig. 5B). Moreover, cleavage of cas-
pase-3 and caspase-9 was attenuated after 48 h in H1299 cells
treated with gemcitabine in the presence of SP600125
(Fig. 5C). These results suggest that JNK activation is required
for gemcitabine-mediated apoptosis through caspase activa-
tion in H1299 cells. To further conﬁrm the eﬀects of JNK
inhibitor SP600125 on gemcitabine-induced apoptosis, we con-
ducted similar studies with dominant-negative mutant vectors
of JNK1 (dnJNK1) and JNK2 (dnJNK2). H1299 cells stably
transfected with either dnJNK1 or dnJNK2 vector plasmid
were treated with 1 lM gemcitabine for 72 h, ﬁxed and stained
with PI, and then analyzed by ﬂow cytometry. The extent of
gemcitabine-mediated apoptosis was reduced in both dnJNK1
and dnJNK2 transfectants than in an empty vector control
(Fig. 5D).
3.6. Transient transfection of a constitutive active JNK1 fusion
construct partially reverses gemcitabine resistance in
H1299/GR cells
To further investigate the role of JNK in gemcitabine resis-
tance, we transiently transfected H1299/GR cells with the plasmid
pSRa 3HA–JNKK2–JNK1, which expresses JNKK2–JNK1, a
fusion protein with constitutive JNK1 activity [18]. The expres-
sion of JNKK2–JNK1 fusion protein was conﬁrmed by
Western blotting with anti-HA antibody (Fig. 6A). To further
investigate whether JNKK2–JNK1 protein expression over-
comes gemcitabine resistance, H1299/GR cells transfected with
HA–JNKK2–JNK1 expressing plasmid were treated with
100 nM gemcitabine for 72 h, and then analyzed apoptotic
Fig. 5. JNK activation has a key role in gemcitabine-induced apoptosis in H1299 cells. (A) H1299 cells were treated with 100 nM gemcitabine (Gem)
in the presence or absence of 20 lM SP600125, and harvested at 24 or 48 h. Whole-cell lysates were analyzed by immunoblotting with indicated
antibodies as further evidence for blocking JNK activation and apoptosis. (B) H1299 cells were treated with 100 nM gemcitabine (Gem) in the
presence or absence of SP600125 (SP) for 48 h, and sub-G1 population, which indicates apoptosis, was determined by FACS analysis. Data represent
the means ± S.D. from three independent experiments. (C) H1299 cells were treated with 100 nM gemcitabine (Gem) in the presence or absence of
20 lM SP600125 for 24 or 48 h. Whole-cell lysates were analyzed by immunoblotting with anti-caspase-9 and anti-caspase-3 antibodies. Arrowheads
represent cleavage proteins. (D) H1299 cells were transfected with plasmid DNA encoding dominant-negative mutant JNK1 or JNK2 and then
selected by G418 to obtain stable clones. Stably transfected H1299 clones were treated with 1 lM gemcitabine for 72 h, and then the apoptotic ratios
were determined by ﬂow cytometry. Results are the means ± S.D. from three independent experiments.
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JNK1 fusion protein partially reversed gemcitabine resistance
in H1299/GR cells. In contrast, JNKK2–JNK1 fusion protein
alone had no detectable eﬀect in apoptotic induction. Apopto-
tic cells after treatment with JNKK2–JNK1 plasmid alone,
gemcitabine alone, and JNKK2–JNK1 plasmid plus gemcita-
bine were 2.4%, 2.3% and 17.3%, respectively. These results
indicate that JNK1 activity is crucial for gemcitabine-mediated
apoptosis and that lack of JNK1 activation will contribute to
gemcitabine resistance.4. Discussion
Although gemcitabine is a promising treatment for NSCLC
[20], the mechanisms of action for gemcitabine, especially the
mechanism of acquired drug resistance, are still controversial,
and there have been no reports about the correlation between
attenuation of JNK activation and gemcitabine resistance. In
the present study, we sought to clarify the mechanism of gem-
citabine resistance by using NSCLC H1299 sublines (H1299/
GR) in which gemcitabine resistance was generated by long-
term exposure to gemcitabine.
A recent report showed that there is a strong inverse corre-
lation between Bcl-xL expression and gemcitabine-induced
apoptosis in some pancreatic cancer cell lines, indicating that
the expression level of Bcl-xL was correlated with gemcitabine
sensitivity [21]. It has also been reported that the level of Bcl-2
is a key factor in determining the sensitivity of cancer cells to
gemcitabine treatment [22,23]. Our result reveals, however,that the expression levels of Bcl-xL and Bcl-2 were no diﬀerent
between H1299 parental cells and H1299/GR cells. This result
suggests that the basal expression levels of those proteins were
not involved in acquired gemcitabine resistance in H1299 cells.
Activation of p38 and Akt has been reported to correlate
with the sensitivity to gemcitabine of pancreatic cancer cell
lines [7,24,25], but our study revealed no diﬀerences in phos-
phorylated Akt and p38 levels at baseline and after gemcita-
bine treatment between H1299 parental cells and H1299/GR
cells. It was also reported that inhibition of ERK activation
by MEK inhibitor or MKP3 plasmid dramatically blocked
gemcitabine-induced cell death in NSCLC cell lines [26]. Our
data also showed that the level of phosphorylated ERK in
H1299 cells was markedly higher than that in H1299/GR cells,
indicating that reduced ERK activation may also be involved
in gemcitabine resistance in H1299/GR cells. Nevertheless,
gemcitabine-induced phosphorylations of JNK, c-Jun and
ATF2 were completely absent in H1299/GR cells, but can be
easily detected in parental H1299 cells, suggesting that JNK
activation might be critical for resistance to gemcitabine.
Although we cannot rule out the possibility that acquired gem-
citabine resistance is associated with other substantial signal-
ing pathways, this result led us to focus on clarifying the role
of JNK activation in gemcitabine-induced cytotoxicity in our
cell lines. To further investigate the role of JNK activation
on the action of gemcitabine, we blocked the JNK signaling
pathway in two ways, by a speciﬁc JNK inhibitor, SP600125,
and by dominant-negative JNK vectors. Our data show that
SP600125 blocked activation of JNK, c-Jun, and ATF2 phos-
phorylation by gemcitabine and strongly diminished gemcita-
Fig. 6. The eﬀect of JNKK2–JNK1 fusion protein expression on
H1299/GR cells. (A) H1299/GR cells were transiently transfected with
JNKK2–JNK1 or plasmid for 24 h, and then whole-cell lysate were
analyzed by immunoblotting with anti-hemagglutinin (HA) antibody.
(B) H1299/GR cells transfected with JNKK2–JNK1 were treated with
100 nM gemcitabine for 72 h, and then ﬁxed cells were analyzed by
ﬂow cytometry. Top panel, histograms show DNA content of cells. The
numbers represent the percentages of sub-G1 cells. Bottom panel,
apoptotic ratio was determined by ﬂow cytometry. Data represent
means ± S.D.
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activation in H1299 cells. It also shows that dominant-negative
vectors of JNK1 or JNK2 diminished gemcitabine-induced
apoptosis. These results strongly indicate that JNK activation
is required for induction of parental H1299 cell death by gem-
citabine.
A previous report showed that JNK activation is involved in
cisplatin-induced apoptosis and that its attenuation correlates
with protection against cisplatin treatment [15]. It was also re-
ported that JNK activation by cisplatin is lower in cisplatin-
resistant sublines of human adenocarcinoma cells and mouse
keratinocytes [27,28]. Another report suggested that inhibition
of JNK by a speciﬁc inhibitor protects KB-3 epidermoid carci-
noma cells from cytotoxicity of drugs such as vinblastine,
doxorubicin, and etoposide [16]. Those ﬁndings indicate that
lack of JNK activation may play a critical role in resistance
of cancer cells to certain chemotherapeutic agents. Moreover,
deactivation of JNK also has been mentioned in clinical stud-
ies in prostate [29] and colon [30] cancers. It was reported that
JNK deactivation in advanced prostate tumors could be re-
lated to a lower apoptotic ratio [29]. An other report showed
a consistent correlation between JNK activation and early
stage NSCLC cancers [31]. The authors of this report sug-
gested that JNK activation could increase the sensitivity of
some NSCLC cells to chemotherapy and radiation therapy.
Further investigation of the role of JNK activation in patients
with NSCLC may give us crucial information about therapeu-
tic strategies against these cancers.A recent report showed that selective JNK stimulation by
transfection of JNK1 lead to apoptosis sensitization to cis-
platin in cisplatin-resistant ovarian cancer cells [32]. Simi-
larly, our data demonstrate that transient transfection of
JNKK2–JNK1 fusion protein partially reverse gemcitabine
resistance in H1299/GR cells. Previous study has revealed
that JNKK2–JNK1 fusion protein has constitutive JNK
activity [18]. Thus, susceptibility to gemcitabine-induced
cytotoxicity can be restored by ectopic expression of JNK
activity. Nevertheless, it is possible that the mechanisms of
gemcitabine resistance could be diﬀerent in diﬀerent cells.
Recent reports implicate expression of ribonucleotide reduc-
tase subunit 1 (RRM1) and deoxycytidine kinase (dCK),
genes that are related to gemcitabine metabolism, in gemcit-
abine resistance [33–35]. It is certainly expected that meta-
bolic inactivation of gemcitabine may lead to resistance to
this agent.
In conclusion, our data demonstrate that JNK activation
has a key role in gemcitabine-mediated cytotoxicity through
induction of apoptosis in NSCLC cells. We also show that
attenuation of JNK activation may contribute to the acquisi-
tion of gemcitabine resistance in lung cancer cells. Thus, the
JNK signaling pathway may be studied further as a critical tar-
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